Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial Capsules: Autoimmune Positioning; Sanofi In China; Migraine Race; BMS Deal; Clinical Advances

Executive Summary

AbbVie outlines how it will stay top dog in autoimmune therapy; Dermira licenses lebrikizumab, threatening pressure on Sanofi/Regeneron's Dupixent; Sanofi has driven up vaccine sales in China after responding to new government distribution rules; Lilly plans a migraine filing; FibroGen, Myokardia and Hansa Medical advance in the clinic and Bristol-Myers shells out up to $2.3bn to turn cold tumors hot. Commercial Capsules rounds up key commercial news reported recently by sister publication Scrip.

Advertisement

Related Content

Adapting To Changing China Regulations Propels Sanofi But How Far?
FibroGen Hails 'Milestone' IPF Data, Phase III And Partners Beckon
MyoKardia Shares Skyrocket On Promising Phase II Data In HCM
Phase III Lasmiditan Data Strengthens Lilly's Dual Migraine Strategy
An Inflammatory Deal: Bristol Commits Up To $2.3bn To Buy IFM Therapeutics
Allergan Focuses On Aesthetics As Sales Dip For Dry Eye Leader Restasis
Safety Issues Not Dampening AbbVie Optimism For Humira Successors

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS121282

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel